Plain-English translation of NCT06675955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is an extension study for people with multiple sclerosis who were already being treated with in an earlier research study. The trial allows you to continue receiving this medication while researchers ask you about how multiple sclerosis affects your physical abilities and daily life. Researchers will also monitor the safety and tolerability of the medication over time.
Many people benefit from ongoing treatment but may not have access to their medication after a research study ends, especially in countries where the treatment isn't yet approved or available. This trial bridges that gap by providing continued access to the medication while gathering important information about how it affects patients' physical function and quality of life.
You likely qualify if…
You likely don't qualify if…
You will continue to receive the medication either as an intravenous infusion (through your vein) or as a subcutaneous injection (under your skin) on a schedule similar to the one you followed in your previous study. Throughout your participation, researchers will ask you questions about how multiple sclerosis affects your physical activities and daily life, and they will monitor you for any side effects. You will remain in the study until the medication becomes available to you locally, you decide to withdraw, or a safety concern arises.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Bulgaria
France